These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 28708207)

  • 1. Variations in transrenal DNA and comparison with plasma DNA as a diagnostic marker for colorectal cancer.
    Tian F; Liao Y; Zhang Y
    Int J Biol Markers; 2017 Oct; 32(4):e434-e440. PubMed ID: 28708207
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potential use of transrenal DNA for non-invasive monitoring and prognosis of colorectal cancer.
    Chen W; Liao Y; Yang C; Fang Z; Liu B; Zheng X; Zhou C
    Biomarkers; 2019 Sep; 24(6):524-529. PubMed ID: 31220949
    [No Abstract]   [Full Text] [Related]  

  • 3. Investigation of transrenal KRAS mutation in late stage NSCLC patients correlates to disease progression.
    Wang X; Meng Q; Wang C; Li F; Zhu Z; Liu S; Shi Y; Huang J; Chen S; Li C
    Biomarkers; 2017 Nov; 22(7):654-660. PubMed ID: 27998182
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cell-free DNA as biomarker and source for mutation detection in primary colorectal cancer.
    Nikolic A; Vlajnic M; Ristanovic M; Petrovic J; Dimitrijevic I; Krivokapic Z; Radojkovic D
    J BUON; 2017; 22(1):178-183. PubMed ID: 28365952
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Urinary measurement of circulating tumor DNA for treatment monitoring and prognosis of metastatic colorectal cancer patients.
    Song T; Mao F; Shi L; Xu X; Wu Z; Zhou J; Xiao M
    Clin Chem Lab Med; 2018 Dec; 57(2):268-275. PubMed ID: 30016269
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Application of Circulating Tumor DNA as a Non-Invasive Tool for Monitoring the Progression of Colorectal Cancer.
    Zhou J; Chang L; Guan Y; Yang L; Xia X; Cui L; Yi X; Lin G
    PLoS One; 2016; 11(7):e0159708. PubMed ID: 27459628
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enumeration and targeted analysis of KRAS, BRAF and PIK3CA mutations in CTCs captured by a label-free platform: Comparison to ctDNA and tissue in metastatic colorectal cancer.
    Kidess-Sigal E; Liu HE; Triboulet MM; Che J; Ramani VC; Visser BC; Poultsides GA; Longacre TA; Marziali A; Vysotskaia V; Wiggin M; Heirich K; Hanft V; Keilholz U; Tinhofer I; Norton JA; Lee M; Sollier-Christen E; Jeffrey SS
    Oncotarget; 2016 Dec; 7(51):85349-85364. PubMed ID: 27863403
    [TBL] [Abstract][Full Text] [Related]  

  • 8. KRAS mutations in tumor tissue and plasma by different assays predict survival of patients with metastatic colorectal cancer.
    Xu JM; Liu XJ; Ge FJ; Lin L; Wang Y; Sharma MR; Liu ZY; Tommasi S; Paradiso A
    J Exp Clin Cancer Res; 2014 Dec; 33(1):104. PubMed ID: 25491325
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection of mutated K-ras DNA in urine, plasma, and serum of patients with colorectal carcinoma or adenomatous polyps.
    Su YH; Wang M; Brenner DE; Norton PA; Block TM
    Ann N Y Acad Sci; 2008 Aug; 1137():197-206. PubMed ID: 18837947
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical relevance of alterations in quantity and quality of plasma DNA in colorectal cancer patients: based on the mutation spectra detected in primary tumors.
    Lin JK; Lin PC; Lin CH; Jiang JK; Yang SH; Liang WY; Chen WS; Chang SC
    Ann Surg Oncol; 2014 Dec; 21 Suppl 4():S680-6. PubMed ID: 24841357
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changes in mutational status during third-line treatment for metastatic colorectal cancer--results of consecutive measurement of cell free DNA, KRAS and BRAF in the plasma.
    Spindler KL; Pallisgaard N; Andersen RF; Jakobsen A
    Int J Cancer; 2014 Nov; 135(9):2215-22. PubMed ID: 24659028
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the prevalence of KRAS-LCS6 polymorphism (rs61764370) within different tumour types (colorectal, breast, non-small cell lung cancer and brain tumours). A study of the Czech population.
    Uvirova M; Simova J; Kubova B; Dvorackova N; Tomaskova H; Sedivcova M; Dite P
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2015 Sep; 159(3):466-71. PubMed ID: 26077004
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection of free-circulating tumor-associated DNA in plasma of colorectal cancer patients and its association with prognosis.
    Lecomte T; Berger A; Zinzindohoué F; Micard S; Landi B; Blons H; Beaune P; Cugnenc PH; Laurent-Puig P
    Int J Cancer; 2002 Aug; 100(5):542-8. PubMed ID: 12124803
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical utility of KRAS status in circulating plasma DNA compared to archival tumour tissue from patients with metastatic colorectal cancer treated with anti-epidermal growth factor receptor therapy.
    Spindler KL; Pallisgaard N; Appelt AL; Andersen RF; Schou JV; Nielsen D; Pfeiffer P; Yilmaz M; Johansen JS; Hoegdall EV; Jakobsen A; Jensen BV
    Eur J Cancer; 2015 Nov; 51(17):2678-85. PubMed ID: 26508156
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of KRAS mutation analysis of primary tumors and matched circulating cell-free DNA in plasmas of patients with colorectal cancer.
    Kuo YB; Chen JS; Fan CW; Li YS; Chan EC
    Clin Chim Acta; 2014 Jun; 433():284-9. PubMed ID: 24685572
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Significance of Combined Measurement of p53 Antibody and other Tumor Markers for Colorectal Cancer after Curative Resection.
    Kawahara D; Fujita F; Hayashi H; Matsuyama T; Eguchi S
    Hepatogastroenterology; 2015 May; 62(139):624-8. PubMed ID: 26897942
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhancing detection of circulating tumor cells with activating KRAS oncogene in patients with colorectal cancer by weighted chemiluminescent membrane array method.
    Yang MJ; Chiu HH; Wang HM; Yen LC; Tsao DA; Hsiao CP; Chen YF; Wang JY; Lin SR
    Ann Surg Oncol; 2010 Feb; 17(2):624-33. PubMed ID: 19937133
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prediagnosis Plasma Adiponectin in Relation to Colorectal Cancer Risk According to KRAS Mutation Status.
    Inamura K; Song M; Jung S; Nishihara R; Yamauchi M; Lochhead P; Qian ZR; Kim SA; Mima K; Sukawa Y; Masuda A; Imamura Y; Zhang X; Pollak MN; Mantzoros CS; Harris CC; Giovannucci E; Fuchs CS; Cho E; Chan AT; Wu K; Ogino S
    J Natl Cancer Inst; 2016 Apr; 108(4):. PubMed ID: 26598515
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epigenome-wide discovery and evaluation of leukocyte DNA methylation markers for the detection of colorectal cancer in a screening setting.
    Heiss JA; Brenner H
    Clin Epigenetics; 2017; 9():24. PubMed ID: 28270869
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnostic and prognostic role of cell-free DNA testing for colorectal cancer patients.
    Bedin C; Enzo MV; Del Bianco P; Pucciarelli S; Nitti D; Agostini M
    Int J Cancer; 2017 Apr; 140(8):1888-1898. PubMed ID: 27943272
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.